Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Harnessing H3K27 acetylation to detect responsiveness to immunotherapies

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on novel predictors of response to immunotherapies in urothelial carcinoma. A transcriptional signature has been derived to identify transcription factors and genes associated with resistance to immunotherapies, based on the acetylation state of the epigenomic mark H3K27. Studies assessing H3K27 acetylation levels both before and after treatment were conducted, in which single-cell analysis has revealed specific immune-related genes that are involved in recruiting T-cells in patients who respond to immunotherapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.